Mayo Clinic Rochester, Rochester, Minnesota, USA.
Henry Ford Hospital, Detroit, Michigan, USA.
Clin Transplant. 2021 Dec;35(12):e14456. doi: 10.1111/ctr.14456. Epub 2021 Nov 9.
Histologic findings on 1-year biopsies such as inflammation with fibrosis and transplant glomerulopathy predict renal allograft loss by 5 years. However, almost half of the patients with graft loss have a 1-year biopsy that is either normal or has only interstitial fibrosis. The goal of this study was to determine if there was a gene expression profile in these relatively normal 1-year biopsies that predicted subsequent decline in renal function. Using transcriptome microarrays we measured intragraft mRNA levels in a retrospective Discovery cohort (170 patients with a normal/minimal fibrosis 1-year biopsy, 54 with progressive decline in function/graft loss and 116 with stable function) and developed a nested 10-fold cross-validated gene classifier that predicted progressive decline in renal function (positive predictive value = 38 ± 34%%; negative predictive value = 73 ± 30%, c-statistic = .59). In a prospective, multicenter Validation cohort (270 patients with Normal/Interstitial Fibrosis [IF]), the classifier had a 20% positive predictive value, 85% negative predictive value and .58 c-statistic. Importantly, the majority of patients with graft loss in the prospective study had 1-year biopsies scored as Normal or IF. We conclude predicting graft loss in many renal allograft recipients (i.e., those with a relatively normal 1-year biopsy and eGFR > 40) remains difficult.
1 年活检的组织学发现,如纤维化炎症和移植肾小球病,可预测 5 年内的肾移植丢失。然而,近一半的移植丢失患者的 1 年活检结果正常或仅有间质纤维化。本研究的目的是确定这些相对正常的 1 年活检中是否存在可预测肾功能随后下降的基因表达谱。我们使用转录组微阵列在回顾性发现队列(170 例 1 年活检正常/轻度纤维化患者,54 例肾功能下降/移植丢失,116 例肾功能稳定)中测量了移植内 mRNA 水平,并开发了一种嵌套的 10 倍交叉验证基因分类器,该分类器可预测肾功能的进行性下降(阳性预测值=38±34%;阴性预测值=73±30%,c 统计量=0.59)。在前瞻性、多中心验证队列(270 例正常/间质纤维化[IF]患者)中,该分类器的阳性预测值为 20%,阴性预测值为 85%,c 统计量为 0.58。重要的是,前瞻性研究中大多数移植丢失患者的 1 年活检评分正常或 IF。我们得出结论,预测许多肾移植受者(即 1 年活检相对正常且 eGFR>40 的受者)的移植丢失仍然困难。